These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 28179071

  • 1. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP3 receptor channels.
    Ivanova H, Luyten T, Decrock E, Vervliet T, Leybaert L, Parys JB, Bultynck G.
    Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071
    [Abstract] [Full Text] [Related]

  • 2. Bcl-2 and IP3 compete for the ligand-binding domain of IP3Rs modulating Ca2+ signaling output.
    Ivanova H, Wagner LE, Tanimura A, Vandermarliere E, Luyten T, Welkenhuyzen K, Alzayady KJ, Wang L, Hamada K, Mikoshiba K, De Smedt H, Martens L, Yule DI, Parys JB, Bultynck G.
    Cell Mol Life Sci; 2019 Oct; 76(19):3843-3859. PubMed ID: 30989245
    [Abstract] [Full Text] [Related]

  • 3. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G, Vervliet T, Akl H, Bultynck G.
    Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
    [Abstract] [Full Text] [Related]

  • 4. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor.
    Monaco G, Decrock E, Nuyts K, Wagner LE, Luyten T, Strelkov SV, Missiaen L, De Borggraeve WM, Leybaert L, Yule DI, De Smedt H, Parys JB, Bultynck G.
    PLoS One; 2013 Apr; 8(8):e73386. PubMed ID: 24137498
    [Abstract] [Full Text] [Related]

  • 5. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl.
    Monaco G, Decrock E, Akl H, Ponsaerts R, Vervliet T, Luyten T, De Maeyer M, Missiaen L, Distelhorst CW, De Smedt H, Parys JB, Leybaert L, Bultynck G.
    Cell Death Differ; 2012 Feb; 19(2):295-309. PubMed ID: 21818117
    [Abstract] [Full Text] [Related]

  • 6. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.
    Vervliet T, Parys JB, Bultynck G.
    Biochem Soc Trans; 2015 Jun; 43(3):396-404. PubMed ID: 26009182
    [Abstract] [Full Text] [Related]

  • 7. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H, Vervloessem T, Kiviluoto S, Bittremieux M, Parys JB, De Smedt H, Bultynck G.
    Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
    [Abstract] [Full Text] [Related]

  • 8. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H, Monaco G, La Rovere R, Welkenhuyzen K, Kiviluoto S, Vervliet T, Molgó J, Distelhorst CW, Missiaen L, Mikoshiba K, Parys JB, De Smedt H, Bultynck G.
    Cell Death Dis; 2013 May 16; 4(5):e632. PubMed ID: 23681227
    [Abstract] [Full Text] [Related]

  • 9. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G, La Rovere R, Karamanou S, Welkenhuyzen K, Ivanova H, Vandermarliere E, Di Martile M, Del Bufalo D, De Smedt H, Parys JB, Economou A, Bultynck G.
    FEBS J; 2018 Jan 16; 285(1):127-145. PubMed ID: 29131545
    [Abstract] [Full Text] [Related]

  • 10. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
    Ivanova H, Ritaine A, Wagner L, Luyten T, Shapovalov G, Welkenhuyzen K, Seitaj B, Monaco G, De Smedt H, Prevarskaya N, Yule DI, Parys JB, Bultynck G.
    Oncotarget; 2016 Aug 23; 7(34):55704-55720. PubMed ID: 27494888
    [Abstract] [Full Text] [Related]

  • 11. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
    Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt H, Mignery GA, Roderick HL, Bootman MD, Distelhorst CW.
    Proc Natl Acad Sci U S A; 2009 Aug 25; 106(34):14397-402. PubMed ID: 19706527
    [Abstract] [Full Text] [Related]

  • 12. Tracing the evolutionary history of Ca2+-signaling modulation by human Bcl-2: Insights from the Capsaspora owczarzaki IP3 receptor ortholog.
    Rosa N, Shabardina V, Ivanova H, Sebé-Pedrós A, Yule DI, Bultynck G.
    Biochim Biophys Acta Mol Cell Res; 2021 Nov 25; 1868(12):119121. PubMed ID: 34400171
    [Abstract] [Full Text] [Related]

  • 13. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR, Zhong F, Chang MJ, Greenberg E, Choudhary Y, Smith MR, McColl KS, Pink J, Reu FJ, Matsuyama S, Distelhorst CW.
    Oncotarget; 2015 Sep 29; 6(29):27388-402. PubMed ID: 26317541
    [Abstract] [Full Text] [Related]

  • 14. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H, La Rovere RM, Janssens A, Vandenberghe P, Parys JB, Bultynck G.
    Int J Dev Biol; 2015 Sep 29; 59(7-9):391-8. PubMed ID: 26260683
    [Abstract] [Full Text] [Related]

  • 15. Profiling of the Bcl-2/Bcl-X(L)-binding sites on type 1 IP(3) receptor.
    Monaco G, Beckers M, Ivanova H, Missiaen L, Parys JB, De Smedt H, Bultynck G.
    Biochem Biophys Res Commun; 2012 Nov 09; 428(1):31-5. PubMed ID: 23058917
    [Abstract] [Full Text] [Related]

  • 16. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage.
    Schulman JJ, Wright FA, Kaufmann T, Wojcikiewicz RJH.
    J Biol Chem; 2013 Aug 30; 288(35):25340-25349. PubMed ID: 23884412
    [Abstract] [Full Text] [Related]

  • 17. The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ signals to mitochondria.
    Monaco G, Decrock E, Arbel N, van Vliet AR, La Rovere RM, De Smedt H, Parys JB, Agostinis P, Leybaert L, Shoshan-Barmatz V, Bultynck G.
    J Biol Chem; 2015 Apr 03; 290(14):9150-61. PubMed ID: 25681439
    [Abstract] [Full Text] [Related]

  • 18. Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.
    Distelhorst CW.
    Biochim Biophys Acta Mol Cell Res; 2018 Nov 03; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [Abstract] [Full Text] [Related]

  • 19. Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2.
    Bittremieux M, La Rovere RM, Akl H, Martines C, Welkenhuyzen K, Dubron K, Baes M, Janssens A, Vandenberghe P, Laurenti L, Rietdorf K, Morciano G, Pinton P, Mikoshiba K, Bootman MD, Efremov DG, De Smedt H, Parys JB, Bultynck G.
    Cell Death Differ; 2019 Mar 03; 26(3):531-547. PubMed ID: 29899382
    [Abstract] [Full Text] [Related]

  • 20. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca2+-dependent mPTP opening.
    Kerkhofs M, La Rovere R, Welkenhuysen K, Janssens A, Vandenberghe P, Madesh M, Parys JB, Bultynck G.
    Cell Calcium; 2021 Mar 03; 94():102333. PubMed ID: 33450506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.